Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
eye diseases | D005128 |
immune system diseases | D007154 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
neuromyelitis optica | EFO_0004256 | D009471 | G36.0 |
Expiration | Code | ||
---|---|---|---|
satralizumab, Enspryng, Genentech, Inc. | |||
2027-08-14 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | — | — | 4 | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | — | 1 | — | — | 1 |
Autoimmune diseases of the nervous system | D020274 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pulmonary arterial hypertension | D000081029 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Satralizumab |
INN | satralizumab |
Description | Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1535963-91-7 |
RxCUI | — |
ChEMBL ID | CHEMBL3833307 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB15762 |
UNII ID | YB18NF020M (ChemIDplus, GSRS) |